| Ytd | -27.92% | |
| 1y | -26.57% |
| Open | 0.80 | Prev Close | 0.78 | Low | 0.77 | High | 0.80 | Mkt Cap | 150.03M |
| Vol | 2.40M | Avg Vol | 1.35M | EPS | -0.41 | P/E | N/A | Forward P/E | -1.12 |
| Beta | 1.10 | Short Ratio | 0.80 | Inst. Own | 4.18% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 0.94 | 200-d Avg | 1.10 | 1yr Est | 3.50 |
LUCD News
Gainers IM Cannabis (NASDAQ:IMCC) stock rose 108.5% to $3.63 during Friday's pre-market session
Ascendiant Capital analyst Edward Woo maintains Lucid Diagnostics (NASDAQ:LUCD) with a Buy and ra
Lucid Diagnostics confirmed its first LBM win with Concert, opens up 10M covered lives. Analyst main
Lucid Diagnostics NASDAQ: LUCD is positioning its EsoGuard test as a non-invasive tool to identify B
Veris Health accelerated its commercial engagement with OSU-The James Veris Health implantable physi
Lucid Diagnostics Inc. (LUCD) Q2 2026 Earnings Call Transcript
Lucid Diagnostics NASDAQ: LUCD reported second-quarter revenue of $1.5 million on 2,770 EsoGuard tes
Lucid Diagnostics (NASDAQ:LUCD) released second-quarter financial results and hosted an earnings cal
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.06 per share versus the Zacks Con
Recognized 2Q26 revenue of $1.5 million Processed 2,770 EsoGuard ® tests Secured first laboratory be
Lucid Diagnostics (NASDAQ:LUCD) reported quarterly losses of $(0.08) per share which missed the anal
Concert's policy recognizes EsoGuard ® as the only esophageal precancer test meeting its coverage cr
NEW YORK, Aug. 4, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Compa
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 31, 2026 /PRNewswire/ -- PAVmed Inc. (Nasd
Conference Call and Webcast at 8:30 AM ET NEW YORK, July 30, 2026 /PRNewswire/ -- Lucid Diagnostics
Lucid Diagnostics offers asymmetric upside, with Medicare reimbursement as a near-term inflection po
Lucid Diagnostics Inc. (LUCD) Shareholder/Analyst Call Prepared Remarks Transcript
Veris Health progressed commercial expansion and advanced implantable physiological monitor developm
Lucid Diagnostics Inc. (LUCD) Q1 2026 Earnings Call Transcript
Lucid Diagnostics NASDAQ: LUCD reported first-quarter 2026 EsoGuard test volume above its pre-Medica
Lucid Diagnostics Inc. (LUCD) came out with a quarterly loss of $0.07 per share versus the Zacks Con
Processed 3,177 EsoGuard ® tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $4
Lucid Diagnostics (LUCD) doesn't possess the right combination of the two key ingredients for a like
Conference Call and Webcast at 8:30 AM ET NEW YORK, May 1, 2026 /PRNewswire/ -- PAVmed Inc. (Nasdaq
Conference Call and Webcast at 8:30 AM ET NEW YORK, April 30, 2026 /PRNewswire/ -- Lucid Diagnostic
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage
Top analysts change outlook on top names, like AA, SSSS, TXN, HQY, LUCD, RPM, PAR, ASRT. Morgan Stan
PAVmed shares pull back Thursday, possibly retracing recent gains on news its subsidiary, Lucid Diag
PAVmed Inc. (PAVM) surges as its subsidiary Lucid Diagnostics (LUCD) secures a contract with VA for
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage,
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage
NEW YORK, Sept. 9, 2025 /PRNewswire/ -- Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the
Lucid Diagnostics Inc. (NASDAQ:LUCD) ("Lucid" or the "Company"), a commercial-stage,
Companies Reporting Before The Bell • Bitcoin Depot (NASDAQ:BTM) is expected to report quarterly lo